Plaque Psoriasis (Psoriasis Vulgaris) – Global Clinical Trials Review, 2022

The global plaque psoriasis (psoriasis vulgaris) clinical trials review report H2 2021 provides an overview of the plaque psoriasis clinical trials scenario. This report provides top-line data relating to the clinical trials on plaque psoriasis. The report also includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. Moreover, the report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type. Additionally, the report provides prominent drugs for in-progress trials (based on the number of ongoing trials).

What are the market dynamics of the global plaque psoriasis clinical trials market?

The number of plaque psoriasis clinical trials conducted globally, has increased for the period 2017-2021. The average number of patients enrolled was highest in the year 2017. More than 20% of trials have been sponsored by institutions and over 70% by companies.

Secukinumab alone or in combination has the highest number of ongoing plaque psoriasis clinical trials.

What are the top regions and countries in the global plaque psoriasis clinical trials market?

In total, more than 1,700 clinical trials were conducted on plaque psoriasis, as of February 2022. Among these trials, over 700 clinical trials were conducted in North America.

Plaque psoriasis clinical trials market in Asia-Pacific

In the Asia-Pacific region, China has the highest number of plaque psoriasis clinical trials followed by Australia, Japan, India, and South Korea.

Plaque psoriasis clinical trials market in Europe

Among the European countries, Germany has the highest number of plaque psoriasis clinical trials, followed by the UK, France, Poland, and Spain.

Plaque psoriasis clinical trials market in North America

In the country-wise analysis, the US has the highest number of plaque psoriasis clinical trials in North America followed by Canada and Mexico.

Plaque psoriasis clinical trials market in the Middle East & Africa

Israel has the highest number of plaque psoriasis clinical trials followed by Iran, South Africa, Egypt, and United Arab Emirates.

Plaque psoriasis clinical trials market in Central & South America

Argentina has the highest number of plaque psoriasis clinical trials in the region followed by Brazil, Colombia, Chile, and Guatemala.

Plaque psoriasis clinical trials market in G7 countries

Among the G7 (the US, the UK, Germany, France, Italy, Canada, and Japan) countries, Canada has the highest proportion of plaque psoriasis to immunology clinical trials as of February 2022. In total, more than 1,800 clinical trials were conducted on plaque psoriasis in G7 countries, of which over 600 clinical trials were in the US.

Plaque psoriasis clinical trials market in E7 countries

Among the E7 (Brazil, Russia, India, China, Mexico, Turkey, and Indonesia) countries, Russia has the highest proportion of plaque psoriasis to immunology clinical trials as of February 2022. In total, more than 470 clinical trials were conducted on plaque psoriasis in E7 Countries, of which over 200 clinical trials were conducted in China.

Global plaque psoriasis clinical trials market, by region

For more regional insights, download a free report sample

What is the phase-wise outlook of the global plaque psoriasis therapeutics clinical trials market?

As of February 2022, more than 490 clinical trials are in Phase II, of which over 50 clinical trials were in progress for the period of 1995-2022. During the same period, more than 220 clinical trials were in progress. The trials that were terminated/suspended or withdrawn accounted for more than 160. This was due to the lack of efficacy, safety, and lack of accrual of subjects.

Global plaque psoriasis clinical trials market, by phase

To know more about key phases, download a free report sample

Who are the key sponsors in the global plaque psoriasis clinical trials market?

The key sponsors in the plaque psoriasis clinical trials market are Novartis AG, LEO Foundation, AbbVie Inc, Johnson & Johnson, Pfizer Inc, Amgen Inc, Eli Lilly and Co, Bristol-Myers Squibb Co, C. H. Boehringer Sohn AG & Co KG, and Bausch Health Companies Inc.

Global plaque psoriasis clinical trials market, by key sponsors

To know more about key sponsors, download a free report sample

Market report scope

 Scope

• The report provides a snapshot of the global clinical trials landscape
• The report provides top-level data related to the clinical trials by region, country (G7 & E7), trial status, trial phase, sponsor type, and endpoint status
• The report reviews top companies involved and enlists all trials (trial title, phase, and status) about the company
• The report provides all the unaccomplished trials (terminated, suspended, and withdrawn) with the reason for unaccomplishment
• The report provides enrollment trends for the past five years
• The report provides the latest news for the past three months

Reasons to Buy

• Assists in formulating key business strategies with regards to investment
• Helps in identifying prominent locations for conducting clinical trials which saves time and cost
• Provides top level analysis of global clinical trials market which helps in identifying key business opportunities
• Supports understanding of trials count and enrollment trends by country in the global therapeutics market
• Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended, or withdrawn) trials
• Facilitates clinical trial assessment of the indication on a global, regional, and country-level